We show you our most important and recent visitors news details Moderna's COVID-19 vaccine becomes 4th jab to get emergency use approval in India in the following article
Hind Al Soulia - Riyadh - NEW DELHI — India’s drug regulatory authority on Tuesday approved Moderna’s coronavirus vaccine for emergency use, making it the fourth jab to get a nod in the country.
The Drugs Controller General of India (DCGI) gave approval to the Indian pharmaceutical company Cipla to import the vaccine for restricted emergency use in the country, local media reported.
"Cipla Limited is supporting Moderna Inc with regulatory approval and import of vaccines to be donated to India. At this stage, there is no definitive agreement on commercial supplies," the Indian company said in a statement.
However, Moderna, the US-based company, announced on Tuesday that the government of India has issued a registration certificate and permission to import its COVID-19 vaccine for restricted use in an emergency situation.
“I want to thank the government of India for this authorization, which marks an important step forward in the global fight against the pandemic,” said Stéphane Bancel, Chief Executive Officer of Moderna.
“We are committed to making our COVID-19 vaccine available around the world.”
Currently, India is currently using three vaccines — Covishield (AstraZeneca), Covaxin and Sputnik V — to inoculate more than 1 billion people against coronavirus. — Agencies
These were the details of the news Moderna's COVID-19 vaccine becomes 4th jab to get emergency use approval in India for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.
It is also worth noting that the original news has been published and is available at Saudi Gazette and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.